Läkemedlet Acomplia (rimonabant) har idag fått så kallad positive opinion från den europeiska läkemedelsmyndigheten EMEA och förväntas därmed bli godkänt i Sverige och övriga Europa. Formellt beslut tas av EU-kommissionen senare i sommar. Sanofi-aventis räknar med att Acomplia kommer att finnas tillgänglig på den svenska marknaden i slutet av det här året.
The 1st quarter 2006 sales & earnings will be released at 7.00 am (Paris time) and will be available online at http://www.sanofi-aventis.com.
As part of its strategy to strengthen its presence in Japan, sanofi-aventis announced today that it has agreed with Astellas Pharma Inc. to accelerate the transfer of all rights to rimonabant in Japan from a joint-venture company held by the two groups to sanofi-aventis.
Achieving good glycemic control with less hypoglycemia and less weight gain
TAXOTERE® RECEIVES POSITIVE OPINION FROM THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE RECOMMENDING APPROVAL IN THE EUROPEAN UNION FOR METASTATIC STOMACH CANCER
TAXOTERE®-based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer
Brigham and Womens Cardiac Group Finds Enoxaparin Strategy is Better Than Commonly Administered Blood Thinning Strategy For Heart Attacks - New therapy significantly reduces risk of repeat heart attack and death
Shikimic acid is a key raw material for the manufacture of Tamiflu®s active ingredient
Results from the IDEA Study Highlight the Rising Worldwide Pandemic of Abdominal Obesity
Om svensken själv får välja är det den tjocka magen som ska bort. 51 procent av svenskarna vill ha smalare midja. En majoritet anger omsorg om hälsan som skäl, inte utseende. Det visar en färsk undersökning från Temo.
NV1FGF Injection Reduces and Delays Risks of Amputation in Patients with Limb Ischemia
Results from the CHARISMA trial showed that the combination of the antiplatelet agents clopidogrel and aspirin did not demonstrate a statistically significant reduction in the risk of heart attack, stroke or cardiovascular death compared to placebo and aspirin in a broad population of patients with either established atherothrombotic disease or multiple risk factors for atherothrombotic events.
New prandial insulin with the OptiClik® delivery system can work with longer-acting insulins, such as basal insulin Lantus®, providing a complementary approach to glucose control
At the request of Apotex and Dr Reddys Laboratories, citing scheduling conflicts for their legal counsels, the U.S. District Court for the Southern District of New York has rescheduled the trial date for the Plavix® patent litigation originally set for April 3, 2006.
Paris, France, February 14, 2006 Sanofi-aventis announced that the results of the RIO North America trial were published today in The Journal of the American Medical Association (JAMA). The trial evaluated two-year treatment with rimonabant in overweight or obese patients, many of whom were at increased risk for diabetes and heart disease through the presence of additional risk factors.
Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has delivered more H5N1 vaccine to the U.S. government including investigational doses formulated with an adjuvant.
Svenska Cardiologföreningen och sanofi-aventis utlyser ett stipendium om 150 000 kronor inom området kardiometabol risk.
The International Union against Cancer (UICC) and sanofi-aventis are launching a mobilisation program against childhood cancer in emerging countries, in preparation for World Cancer Day, February 4, 2006.
Excellent performance from vaccines: up 26.9% on a comparable basis1 2005 adjusted earnings1 guidance raised Approval of Plavix® in Japan
Paris - January 24, 2006 - Sanofi-aventis (EURONEXT : SAN and in New York NYSE : SNY) announced today that the antiplatelet agent Plavix® (clopidogrel) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the reduction of recurrence after ischemic cerebrovascular disorder.